(Originally published on Nov 12, 2020)
To win the battle with SARS-CoV-2 ENDECE a revolutionary biotech company based in Portland, OR. has developed a biotherapeutic designed to regain control of immune response preventing ARDS (Acute Respiratory Distress Syndrome). Historically vaccines have played an important role in the prevention of many diseases. However, the overall effect of a vaccine within society depends on both efficacy and percent of the population that gets vaccinated.
For example, if the Pfizer vaccine is 90% effective, as projected, and half of the population receives the vaccine, over 50% of the population will remain unprotected.
Statistically, by easing compliance with mandates like wearing a mask, it is projected that up to 700,000 new cases of COVID-19 may take place in the US by December 31 of 2020, per day.
https://www.statista.com/statistics/1176657/covid-projected-new-cases-per-day-by-scenario-us/
SAVRS-CoV-2 is an aggressive virus that thrives in the pulmonary system and leads to COVID-19 and Acute Respiratory Distress Syndrome (ARDS). It overwhelms the body’s natural immune system, causes respiratory distress, respiratory failure, and potentially death. In addition to a vaccine, a biotherapeutic is needed to reduce inflammation and viral load within the pulmonary system.
Biotech company, ENDECE did just that. We looked outside the box to develop NDC-1308, a biotherapeutic that works at the gene level to reduce inflammation and viral load within the pulmonary system. Either alone or in combination with a vaccine, biotherapeutic NDC-1308 may help to win the battle against viruses like SARS-CoV-2 / COVID-19 as well as any future SARS and pulmonary viruses that cause Acute Respiratory Distress Syndrome (ARDS).